Zelira Therapeutics has licensed its ZTL-106 cannabinoid formulation to Levin Health for a study of retired athletes suffering from chronic pain.

Levin Health will fund the clinical trial with Zelira project managing it at La Trobe University’s Sport and Exercise Medicine Research Centre.

Levin Health CEO Mark Brayshaw

Studies show retired athletes are more likely to suffer chronic pain and associated conditions such as depression and anxiety as a result of injuries and physical exertion over long periods of time.

Levin Health CEO Mark Brayshaw said: “Quality clinical trial data is a vital requirement to validate cannabinoids as medicine, and Zelira are doing some of the best clinical work in the sector.

“Chronic pain is one of the major health issues facing not just athletes, but all active Australians, and we have high hopes for the trial.”

The eventual aim is to build an international brand supported by clinical data with the companies entering into a profit share arrangement.

Zelira will hold marketing rights for North and South America with Levin Health holding rights to all other global markets.